AACR Annual Meeting, San Diego (Virtual), April 2020:
‘Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer’
Spicer J, Basu B, Montes M, Banerji U, Kristeleit R, Veal G, Corrigan C, Till S, Nintos G, Brier T, Funingana I, Ang J, ZakiK, Griffin A, Barton C, Jones P, Mellor S, Brook S, Stoddart K, Selkirk C, Carroll S, Lentfer H, Woodman N, Pope A, Pellizzari G, Nakamura M, Ilieva K, Khiabany A, Stavraka C, Gould H, Chauhan J, Bax H, Pinder P, Josephs D & Karagiannis S
‘MTL-CEBPA, a small activating RNA therapeutic up-regulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multi-centre, open-label, Phase I trial’
Sarker D, Plummer R, Meyer T, Sodergren M, Basu B, Chee CE, Huang K, Palmer D, Ma Y, Evans T, Spalding R, Pai M, Sharma R, Pinato D, Spicer J, Hunter S, Kwatra V, Nicholls J, Collin D, Nutbrown R, Glenny H, Fairbairn S, Reebye V, Voutila J, Dorman S, Andrikakou P, Lloyd P, Felstead S, Vasara J, Habib R, Wood C, Sætrom P, Huber H, Blakey D, Rossi J & Habib N
Clinical Cancer Research (2020) doi: 10.1158/1078-0432.CCR-20-0414
ESMO Annual Meeting, Barcelona, September 2019:
‘An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer’
Spicer J, Provencio M, Garrido Lopez P, Bosch-Barrera J, de Castro Carpeño F, Felip E, Trigo J, Viteri S, Coart E, Schmidt E, Christiansen A, Zocca M, Andersen M, Ehrnrooth E & Paz-Ares L
‘A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer’
Macpherson IR, Spiliopoulou P, Rafii S, Saggese M, Baird RD, Garcia-Corbacho J, Italiano A, Bonneterre J, Campone M, Cresti N, Posner J, Takeda Y, Arimura A & Spicer J
Breast Cancer Research (2019) 22:1
‘A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors’
O’Brien M, Sarker D, Bhosle J, Thillai K, Yap T, Uttenreuther-Fischer M, Pemberton K, Jin X, Wiebe S, de Bono J & Spicer J
Cancer Chemotherapy and Pharmacology (2018) 82:757-66
‘Anti-folate receptor-α IgE but not IgG recruits macrophages to attack tumors via TNF-α/MCP-1 signaling’
Josephs D, Bax H, Dodev T, Georgouli M, Nakamura M, Pellizzari G, Saul L, Karagiannis P, Cheung A, Herraiz C, Ilieva K, Correa I, Fittall M, Crescioli S, Gazinska P, Woodman N, Mele S, Chiaruttini G, Gilbert AE, Koers A, Bracher M, Selkirk C, Lentfer H, Barton C, Lever E, Muirhead G, Tsoka S, Canevari S, Figini M, Montes A, Downes N, Dombrowicz D, Corrigan C, Beavil AJ, Nestle F, Jones P, Gould H, Sanz-Moreno V, Blower P, Spicer J & Karagiannis S
Cancer Research (2017) 77:1127-1141
